Systemic sclerosis & Raynaud's
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis
Main finding · Clinical features of anti-NVL positive vs negative patientsResult — go to the resultOdds ratio 16.3Authors' conclusion
We identified NVL as a new autoantibody target by a novel protein IP assay in SSc patients with a homogeneous nucleolar IIF pattern, testing negative for all known SSc-specific autoantibodies by commercial assays and RNA IP. Anti-NVL identifies a new clinical phenotype, characterized by calcinosis and cancer.
Study context
- Population
- Systemic sclerosis (SSc) patients; those negative for all SSc-specific autoantibodies (n = 51) and 56 with nucleolar indirect immunofluorescence (IIF) pattern tested by protein immunoprecipitation (IP)
- Participants
- 307 SSc patients
- Exposure
- Anti-NVL positive vs anti-NVL negative SSc patients
- Negativen = 101reference
- Outcome
- Identification of new SSc-related autoantibodies by a novel protein IP assay
Methodological detailsnovel non-radioactive protein immunoprecipitation assay, mass spectrometry, western blot confirmation
- Novel non-radioactive protein immunoprecipitation assay
- Mass spectrometry
- Western blot confirmation
Main finding
As reported in the abstract
Clinical features of anti-NVL positive vs negative patients
Odds ratio
16.3
P = 0.024
- Calcinosis: 100% vs 18.9%
- P < 0.001
- Cancer: 66.7% vs 8.9%
- P = 0.002
- Anti-NVL detected by protein IP (110-115kDa band, homogeneous nucleolar IIF)
- Five patients
Observational data: associations, not effects.
Further findings
Calcinosis
P < 0.001
Cancer
P = 0.002
Original publication
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis. Rheumatology (Oxford). Published 28 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →